by Market Overview:
Eosinophilic Esophagitis is a chronic inflammatory disorder of the esophagus characterized by elevated numbers of eosinophils in the esophagus. The disease causes symptoms such as difficulty swallowing, nausea, vomiting and abdominal pain. Drugs such as corticosteroids and mast-cell stabilizers have shown effectiveness in treating EoE symptoms. The rising prevalence of EoE globally has fuelled the need for effective treatment options.
Market key trends:
One of the key trends in the Eosinophilic Esophagitis market is the rising pipeline of drugs in late-stage clinical trials. Several companies are focusing on developing novel targeted therapies for EoE. For instance, Allakos Inc.’s AK002 is currently in Phase 3 trials for treating EoE. Glenmark Pharmaceuticals also has GBR 830, an oral interleukin-13 antagonist in Phase 2 trials. Increased R&D investments by players in developing novel therapeutics are expected to drive the market growth over the forecast period.
The global Eosinophilic Esophagitis Market Growth is estimated to be valued at US$ 245.92 Mn in 2023 and is expected to exhibit a CAGR of 33.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate due to the high capital requirement for research and development in the eosinophilic esophagitis market.
Bargaining power of buyers: The bargaining power of buyers is moderate as the treatment options available are limited.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the presence of many suppliers in the market providing raw materials and drugs.
Threat of new substitutes: The threat of new substitutes is low as no direct substitute is currently available for the treatment of eosinophilic esophagitis.
Competitive rivalry: Competition in the market is high among major players.
Key Takeaways
The global eosinophilic esophagitis market is expected to witness high growth, exhibiting 33% CAGR over the forecast period, due to increasing prevalence of gastrointestinal disorders and food allergies.
Regional analysis
North America is expected to dominate the global eosinophilic esophagitis market throughout the forecast period. This is attributed to the growing incidence of eosinophilic esophagitis and presence of key players in the region. Asia Pacific is anticipated to exhibit the fastest growth in the market over the forecast period owing to rising awareness regarding the disease, improving healthcare infrastructure and increasing healthcare spending.
Key players
Key players operating in the eosinophilic esophagitis market are Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH.
